Fiche publication
Date publication
décembre 2004
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BALDAUF Jean-Jacques
Tous les auteurs :
Weingertner AS, Hamid D, Baldauf JJ, Nisand I
Lien Pubmed
Résumé
Mifepristone, a derivative of norethindrone, a first generation synthetic progestative, has a very potent antiprogestative activity and to a lesser degree antiandrogenic and antiglucocorticoid activities. This action makes it potentially useful in the treatment of multiple hormone dependent diseases in obstetrics-gynecology as well as in a variety of medical specialties such as neurology, ophthalmology, and oncology. Nevertheless, the label of abortive pill has incited numerous ethical and political debates concerning the permission to market this drug, and this has contributed to the delay in the assessment of the potential indications of mifepristone. Largely under-utilized in practice despite its increasing theoretical benefit, clinical studies should now de conducted. Thus, based on an international review of literature during the last ten years, we have shed light on the present and potential indications of mifepristone in medical practice.
Référence
J Gynecol Obstet Biol Reprod (Paris). 2004 Dec;33(8):692-702.
